Skip to main content
. 2017 Feb 15;9:139–147. doi: 10.2147/CEOR.S124381

Figure 1.

Figure 1

Survival times – discontinuation due to inefficacy by drug.

Abbreviations: ADA, adalimumab; CTZ, certolizumab pegol; ETA, etanercept; GOL, golimumab; INF, infliximab; RTX, rituximab; TCZ, tocilizumab.